Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 113

1.

Multimodal treatment of advanced renal cancer in 2017.

Mennitto A, Verzoni E, Grassi P, Ratta R, Fucà G, Procopio G.

Expert Rev Clin Pharmacol. 2017 Oct 6:1-8. doi: 10.1080/17512433.2017.1386552. [Epub ahead of print]

PMID:
28956645
2.

Castration-naive metastatic prostate cancer: reshaping old paradigms.

Ratta R, Grassi P, Fucà G, Verzoni E, Procopio G.

Expert Rev Anticancer Ther. 2017 Oct;17(10):879-881. doi: 10.1080/14737140.2017.1374178. Epub 2017 Sep 11. No abstract available.

PMID:
28854837
3.

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?

Grassi P, Verzoni E, Ratta R, Porcu L, Prisciandaro M, Mennitto A, Calareso G, de Braud F, Procopio G.

Drugs R D. 2017 Aug 11. doi: 10.1007/s40268-017-0203-y. [Epub ahead of print]

PMID:
28801802
4.

Correlations Between Personality, Affective and Filial Self-Efficacy Beliefs, and Psychological Well-Being in a Sample of Italian Adolescents.

Tommasi M, Grassi P, Balsamo M, Picconi L, Furnham A, Saggino A.

Psychol Rep. 2017 Jan 1:33294117720698. doi: 10.1177/0033294117720698. [Epub ahead of print]

PMID:
28750584
5.

Pure small cell recurrent prostate cancer developing syndrome of inappropriate antidiuretic hormone secretion.

Peverelli G, Grassi P.

Tumori. 2017 Jun 14:0. doi: 10.5301/tj.5000651. [Epub ahead of print]

PMID:
28623637
6.

Effects of altered sialic acid biosynthesis on N-linked glycan branching and cell surface interactions.

Pham ND, Pang PC, Krishnamurthy S, Wands AM, Grassi P, Dell A, Haslam SM, Kohler JJ.

J Biol Chem. 2017 Jun 9;292(23):9637-9651. doi: 10.1074/jbc.M116.764597. Epub 2017 Apr 19.

7.

Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.

Pusceddu S, Verzoni E, Prinzi N, Mennitto A, Femia D, Grassi P, Concas L, Vernieri C, Lo Russo G, Procopio G.

Ther Adv Med Oncol. 2017 Mar;9(3):183-188. doi: 10.1177/1758834016683905. Epub 2017 Jan 11. Review.

8.

Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents.

Grassi P, Doucet L, Giglione P, Grünwald V, Melichar B, Galli L, De Giorgi U, Sabbatini R, Ortega C, Santoni M, Bamias A, Verzoni E, Derosa L, Studentova H, Porcu L, De Braud F, Porta C, Procopio G.

Oncology. 2017;92(5):269-275. doi: 10.1159/000455970. Epub 2017 Feb 17.

PMID:
28208153
9.

What advances have been made in immune-therapy for renal cell carcinoma?

Verzoni E, Grassi P, Ratta R.

Future Oncol. 2017 Apr;13(8):665-668. doi: 10.2217/fon-2017-0026. Epub 2017 Feb 10. No abstract available.

10.

Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience.

De Gobbi A, Biasoni D, Catanzaro M, Nicolai N, Piva L, Stagni S, Torelli T, Procopio G, Verzoni E, Grassi P, Colecchia M, Paolini B, Spreafico C, Marchianò A, Salvioni R.

Tumori. 2017 Jan 7:0. doi: 10.5301/tj.5000596. [Epub ahead of print]

PMID:
28085177
11.

Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice.

Grassi P, Verzoni E, Mennitto A, Procopio G.

Transl Androl Urol. 2016 Dec;5(6):974-976. doi: 10.21037/tau.2016.11.06. No abstract available.

12.

Does F-18 FDG-PET still play a role in metastatic renal cell carcinoma?

Mennitto A, Grassi P, Verzoni E, Ratta R, Procopio G.

J Med Imaging Radiat Oncol. 2017 Apr;61(2):250-251. doi: 10.1111/1754-9485.12575. Epub 2017 Jan 9. No abstract available.

PMID:
28070961
13.

Radiotherapy for the treatment of thyroid eye disease-a prospective comparison: Is orbital radiotherapy a suitable alternative to steroids?

Grassi P, Strianese D, Piscopo R, Pacelli R, Bonavolontà G.

Ir J Med Sci. 2017 Jan 3. doi: 10.1007/s11845-016-1542-3. [Epub ahead of print]

PMID:
28050807
14.

Central retinal vein occlusion associated with high blood levels of lipoprotein (a).: Is lipoprotein (a) a reliable marker for identification of predisposed individuals?

Grassi P, Salicone A, Motta L, Motta MS.

Saudi J Ophthalmol. 2016 Oct-Dec;30(4):250-252. doi: 10.1016/j.sjopt.2016.11.001. Epub 2016 Nov 10.

15.

Scene segmentation in early visual cortex during suppression of ventral stream regions.

Grassi PR, Zaretskaya N, Bartels A.

Neuroimage. 2017 Feb 1;146:71-80. doi: 10.1016/j.neuroimage.2016.11.024. Epub 2016 Nov 12.

PMID:
27847346
16.

Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.

Verzoni E, De Giorgi U, Derosa L, Caffo O, Boccardo F, Facchini G, Porcu L, De Vincenzo F, Zaniboni A, Chiuri VE, Fratino L, Santini D, Adamo V, De Vivo R, Dinota A, Messina C, Ricotta R, Caserta C, Scavelli C, Susi M, Tartarone A, Surace G, Mosca A, Bruno M, Barni S, Grassi P, Procopio G.

Oncotarget. 2016 Jun 28;7(26):40085-40094. doi: 10.18632/oncotarget.9485.

17.

Thromboelastographic predictors of venous thromboembolic events in critically ill patients: are we missing something?

Tartamella F, Vassallo MC, Berlot G, Grassi P, Testa F.

Blood Coagul Fibrinolysis. 2016 Oct;27(7):804-811.

PMID:
26895213
18.

The Role of the Occipital Cortex in Resolving Perceptual Ambiguity.

Grassi PR, Schauer G, Dwarakanath A.

J Neurosci. 2016 Oct 12;36(41):10508-10509. No abstract available.

19.

Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience.

Mennitto A, Grassi P, Ratta R, Verzoni E, Prisciandaro M, Procopio G.

Ther Adv Urol. 2016 Oct;8(5):319-326. Epub 2016 Jul 7. Review.

20.

Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors.

Verzoni E, Grassi P, Ratta R, Niger M, De Braud F, Valdagni R, Procopio G.

Ther Adv Med Oncol. 2016 Sep;8(5):323-30. doi: 10.1177/1758834016656493. Epub 2016 Jul 5.

Supplemental Content

Loading ...
Support Center